Next Article in Journal
Narrative Review of Biological Markers in Chronic Limb-Threatening Ischemia
Previous Article in Journal
Photodynamic Therapy for the Treatment of Bowen’s Disease: A Review on Efficacy, Non-Invasive Treatment Monitoring, Tolerability, and Cosmetic Outcome
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Štofilová et al. Probiotic-Based Intervention in the Treatment of Ulcerative Colitis: Conventional and New Approaches. Biomedicines 2022, 10, 2236

Center of Clinical and Preclinical Research MEDIPARK, Faculty of Medicine, Pavol Jozef Safarik University in Kosice, Trieda SNP 1, 040 11 Kosice, Slovakia
*
Author to whom correspondence should be addressed.
Biomedicines 2024, 12(4), 797; https://doi.org/10.3390/biomedicines12040797
Submission received: 31 January 2024 / Accepted: 13 March 2024 / Published: 3 April 2024
(This article belongs to the Section Microbiology in Human Health and Disease)

Text Correction

The authors would like to add the following clarification regarding the clinical trials evaluating the probiotic product VSL#3 cited in the published paper [1]. A correction has been made to Paragraph 1 in Section 3.2. Effectiveness of Conventional Probiotics in Clinical Trials. “All studies cited in this paper assessed a probiotic formulation previously known as VSL#3. The formulation of the probiotic product VSL#3, which is currently marketed under this brand name, is not identical to the original product, which since 2016 has been known under the generic name ‘De Simone Formulation’ and is available on the market under the brand names Visbiome (USA) and Vivomixx (Europe).”
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Štofilová, J.; Kvaková, M.; Kamlárová, A.; Hijová, E.; Bertková, I.; Gul’ašová, Z. Probiotic-Based Intervention in the Treatment of Ulcerative Colitis: Conventional and New Approaches. Biomedicines 2022, 10, 2236. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Štofilová, J.; Kvaková, M.; Kamlárová, A.; Hijová, E.; Bertková, I.; Guľašová, Z. Correction: Štofilová et al. Probiotic-Based Intervention in the Treatment of Ulcerative Colitis: Conventional and New Approaches. Biomedicines 2022, 10, 2236. Biomedicines 2024, 12, 797. https://doi.org/10.3390/biomedicines12040797

AMA Style

Štofilová J, Kvaková M, Kamlárová A, Hijová E, Bertková I, Guľašová Z. Correction: Štofilová et al. Probiotic-Based Intervention in the Treatment of Ulcerative Colitis: Conventional and New Approaches. Biomedicines 2022, 10, 2236. Biomedicines. 2024; 12(4):797. https://doi.org/10.3390/biomedicines12040797

Chicago/Turabian Style

Štofilová, Jana, Monika Kvaková, Anna Kamlárová, Emília Hijová, Izabela Bertková, and Zuzana Guľašová. 2024. "Correction: Štofilová et al. Probiotic-Based Intervention in the Treatment of Ulcerative Colitis: Conventional and New Approaches. Biomedicines 2022, 10, 2236" Biomedicines 12, no. 4: 797. https://doi.org/10.3390/biomedicines12040797

APA Style

Štofilová, J., Kvaková, M., Kamlárová, A., Hijová, E., Bertková, I., & Guľašová, Z. (2024). Correction: Štofilová et al. Probiotic-Based Intervention in the Treatment of Ulcerative Colitis: Conventional and New Approaches. Biomedicines 2022, 10, 2236. Biomedicines, 12(4), 797. https://doi.org/10.3390/biomedicines12040797

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop